Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.

Abstract:

:Introduction: Cyclin-dependent kinase 7 (CDK7) is a part of the CDK-activating kinase family (CAK) which has a key role in the cell cycle and transcriptional regulation. Several lines of evidence suggest that CDK7 is a promising therapeutic target for cancer. CDK7 selective inhibitors such as SY-5609 and CT7001 are in clinical development. Areas covered: We explore the biology of CDK7 and its role in cancer and follow this with an evaluation of the preclinical and clinical progress of CDK7 inhibitors, and their potential in the clinic. We searched PubMed and ClinicalTrials to identify relevant data from the database inception to 14 October 2020. Expert opinion: CDK7 inhibitors are next generation therapeutics for cancer. However, there are still challenges which include selectively, side effects, and drug resistance. Nevertheless, with ongoing clinical development of these inhibitors and greater analysis of their target, CDK7 inhibitors will become a promising approach for treatment of cancer in the near future.

authors

Liang H,Du J,Elhassan RM,Hou X,Fang H

doi

10.1080/13543784.2021.1850693

subject

Has Abstract

pub_date

2021-01-01 00:00:00

pages

61-76

issue

1

eissn

1354-3784

issn

1744-7658

journal_volume

30

pub_type

杂志文章
  • Novel approaches for the prevention of restenosis.

    abstract::Restenosis, the re-narrowing of the lumen of the coronary artery, in the months following a successful percutaneous balloon angioplasty or stenting, remains the main limitation to percutaneous coronary revascularisation. Serial intravascular ultrasound studies have shown that restenosis after conventional balloon angi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.11.2555

    authors: Gruberg L,Waksman R,Satler LF,Pichard AD,Kent KM

    更新日期:2000-11-01 00:00:00

  • Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels.

    abstract:INTRODUCTION:Thermo transient receptor potential (thermoTRP) channels are some of the most intensely pursued therapeutic targets of the past decade. They are considered promising targets of numerous diseases including chronic pain and cancer. Modulators of these proteins, in particular TRPV1-4, TRPM8 and TRPA1, have re...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2020.1825680

    authors: Fernández-Carvajal A,González-Muñiz R,Fernández-Ballester G,Ferrer-Montiel A

    更新日期:2020-11-01 00:00:00

  • Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial.

    abstract:BACKGROUND:Age-related macular degeneration is the leading cause of blindness among elderly individuals in industrialized countries. New drugs and advanced concepts for the treatment of dry AMD (dAMD) are needed. A new approach is the application of intravenous infusions of prostaglandin E1. OBJECTIVE:The aim of this ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1517/13543784.2013.794782

    authors: Augustin AJ,Diehm C,Grieger F,Bentz J

    更新日期:2013-07-01 00:00:00

  • Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine?

    abstract:IMPORTANCE OF THE FIELD:Migraine is an episodic, substantially inherited brain disorder affecting 15% of adults in Western Europe and North America, and is one of the commonest reasons for patients to see their physicians. While the World Health Organization considers that severe migraine can be as disabling as quadrip...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543781003691832

    authors: Marin JC,Goadsby PJ

    更新日期:2010-04-01 00:00:00

  • Are compounds acting at metabotropic glutamate receptors the answer to treating depression?

    abstract::Numerous studies over the last few years have suggested that modulating the glutamatergic system may be an efficient method to achieve an antidepressant effect. Data suggest that metabotropic glutamate receptors (mGlu receptors), related to long-term, modulatory effects on glutamatergic neurotransmission, may be a goo...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.12.1545

    authors: Palucha A

    更新日期:2006-12-01 00:00:00

  • Drug delivery across the skin.

    abstract::Since the introduction of the first through the skin (TTS) therapeutic in 1980, a total of 34 TTS products have been marketed and numerous drugs have been tested by more than 50 commercial organisations for their suitability for TTS delivery. Most of the agents which have been tested have had low molecular weights, du...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.12.1887

    authors: Cevc G

    更新日期:1997-12-01 00:00:00

  • Recent developments in the pharmacological treatment of Parkinson's disease.

    abstract::Parkinson's disease (PD) is a neurodegenerative disorder associated with the loss of dopaminergic neurons in the substantia nigra. The decline of dopamine leads to motor dysfunctions manifested as tremor, rigidity and bradykinesia. The pharmacological treatment of choice for the past 30 years has primarily been the do...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.8.1335

    authors: Tuite P,Riss J

    更新日期:2003-08-01 00:00:00

  • Fatty acid synthase inhibitors: new directions for oncology.

    abstract::Fatty acid synthase (FASN) is the enzyme that catalyzes the de novo synthesis of fatty acids in cells. Because of the strong expression in many cancers, FASN is an attractive and tractable target for therapeutic intervention. The discovery and development of pharmacologic agents that block FASN activity highlight the ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.11.1817

    authors: Kridel SJ,Lowther WT,Pemble CW 4th

    更新日期:2007-11-01 00:00:00

  • American Association for Cancer Research 1997: progress and new hope in the fight against cancer.

    abstract::Considerable progress has been made with tyrosine kinase inhibitors. After long and sustained efforts, several tyrosine kinase inhibitors with convincing in vivo experimental antitumour properties such as CP-358,774, ZD 1839, CEP-751 are entering Phase I clinical trials. Significant in vivo experimental antitumour act...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.6.771

    authors: Lavelle F

    更新日期:1997-06-01 00:00:00

  • Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.

    abstract:INTRODUCTION:Signal transducer and activator of transcription 3 (STAT3) controls a key signaling pathway in the development of many malignant diseases. Several genetic studies have proven its central role in the regulation of apoptosis, proliferation, angiogenesis and immune responses making it an attractive target for...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2011.601739

    authors: Mankan AK,Greten FR

    更新日期:2011-09-01 00:00:00

  • XIAP antisense therapy with AEG 35156 in acute myeloid leukemia.

    abstract:INTRODUCTION:AEG 35156 is an antisense oligonucleotide to X-linked inhibitor of apoptosis protein (XIAP). Overexpression of XIAP is common in acute myeloid leukemia (AML) and other cancers and is thought to cause resistance to cancer therapy. Effective treatment options for patients with relapsed or refractory AML are ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2013.789498

    authors: Katragadda L,Carter BZ,Borthakur G

    更新日期:2013-05-01 00:00:00

  • Current status and future development of antitubercular chemotherapy.

    abstract::Tuberculosis (TB), which kills more people than any other infectious disease, was declared a global emergency by the World Health Organization in 1993. The emergence of new Mycobacterium tuberculosis strains that are resistant to some or all current antitubercular drugs seriously hampers the control of the disease. Up...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.8.1033

    authors: Kremer LS,Besra GS

    更新日期:2002-08-01 00:00:00

  • New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca2+ channel blocker.

    abstract::Intravenous antihypertensive agents are used in clinical situations in which the immediate, precise control of blood pressure is a clinical necessity. Clevidipine is a new, vascular-selective, dihyrdopyridine Ca(2+) channel blocker, which exerts its hemodynamic effects through selective arterial vasodilation without e...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.9.1449

    authors: Gradman AH,Vivas Y

    更新日期:2007-09-01 00:00:00

  • Fertilisation Promoting Peptide: a key player in male fertility/subfertility?

    abstract::'Male factor' problems contribute to subfertility in a significant proportion of couples. In some instances, defective sperm production has qualitative and/or quantitative effects on the semen profile; in others, no obvious defects can be detected, yet spermatozoa are non-fertilising. Recent studies have revealed that...

    journal_title:Expert opinion on investigational drugs

    pub_type: 社论

    doi:10.1517/13543784.6.12.1797

    authors: Fraser LR

    更新日期:1997-12-01 00:00:00

  • Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease.

    abstract::There is a growing understanding of the central role that platelets play in coronary artery disease. The glycoprotein IIb/IIIa receptor has recently been identified as the final common pathway for platelet aggregation and hence has been the focus of many clinical trials to influence various aspects of coronary artery ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.11.1645

    authors: Salam AM,Suwaidi JA

    更新日期:2002-11-01 00:00:00

  • New antithrombotic drugs on the horizon.

    abstract::Venous and arterial thromboembolism are a major cause for morbidity and mortality. The list of established drugs for the prevention of thrombus formation and embolisation includes heparins, hirudin and derivatives, aspirin, ADP and glycoprotein IIb/IIIa receptor antagonists, as well as vitamin K antagonists. Several l...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.5.781

    authors: Ruef J,Katus HA

    更新日期:2003-05-01 00:00:00

  • An array of immunotherapeutic strategies for B-cell lymphomas.

    abstract::With FDA approval of monoclonal antibodies (mAb) against the B-cell-specific cell surface molecule CD20, immunotherapy in B-cell non-Hodgkin's-lymphomas (NHL) has gained momentum. Since the first description of the CD20 mAb and its use in a single patient, it has taken more than 20 years to implement this in current t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.8.12.2059

    authors: Schultze JL

    更新日期:1999-12-01 00:00:00

  • Clinical pharmacology study of the corticosteroid nasal spray dexamethasone cipecilate (NS-126): examination of the durability of efficacy in the nasal induction test.

    abstract:BACKGROUND:Dexamethasone cipecilate is a corticosteroid nasal spray whose local efficacy durability has been improved by introduction of a liposoluble functional group to its chemical structure. This study was conducted to evaluate the efficacy of once-daily treatment with this drug in patients with perennial allergic ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/13543784.2010.531258

    authors: Gotoh M,Okubo K,Okuda M,Hamada C

    更新日期:2010-12-01 00:00:00

  • Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors.

    abstract:INTRODUCTION:Metastases to the central nervous system are the most common cause of malignant intracranial tumors in adults. Current standard of care includes surgery and radiation, but overall survival remains poor. A range of systemic therapies are emerging as promising treatment options for these patients. AREAS COV...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2020.1836154

    authors: McMahon JT,Faraj RR,Adamson DC

    更新日期:2020-12-01 00:00:00

  • Recent advances in the development of haemoglobin-based blood substitutes.

    abstract::The term 'blood substitute' is commonly used to describe products which can carry and deliver oxygen. These products are also referred to as 'oxygen carriers' or 'oxygen therapeutics'. Blood substitutes are a new generation of oxygen therapeutics and their introduction will redefine treatment approaches in a wide rang...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.11.1659

    authors: Gulati A

    更新日期:1997-11-01 00:00:00

  • Antisense approach for the treatment of cytomegalovirus infection.

    abstract::Human cytomegalovirus (HCMV) is the most common viral opportunistic infection in patients suffering with acquired immunodeficiency virus (AIDS). HCMV is a systemic infection that may infect several sites in the body, including the retina, gastrointestinal tract, lungs, liver, and central nervous system. Retinitis is t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.9.1157

    authors: Temsamani J,Pari GS,Guinot P

    更新日期:1997-09-01 00:00:00

  • Proteasome inhibitors: possible novel therapeutic strategy for ischemia-reperfusion injury?

    abstract:INTRODUCTION:The ubiquitin-proteasome system (UPS) is responsible for the degradation of misfolded or damaged proteins, regulating inflammatory processes and cell cycle progression. The aim of this article is to summarize the currently available data regarding the possible utility of proteasome inhibitors (PIs) in the ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2013.840287

    authors: Kandilis AN,Karidis NP,Kouraklis G,Patsouris E,Vasileiou I,Theocharis S

    更新日期:2014-01-01 00:00:00

  • More light at the end of the tunnel - apixaban in atrial fibrillation.

    abstract:INTRODUCTION:Subjects with atrial fibrillation are at risk of thromboembolic events. The vitamin K antagonists (e.g., warfarin) are useful at preventing coagulation in atrial fibrillation, but are difficult to use. One of the FXa inhibitors, oral apixaban, has been tested as an anticoagulant in atrial fibrillation. AR...

    journal_title:Expert opinion on investigational drugs

    pub_type: 评论,杂志文章

    doi:10.1517/13543784.2012.696611

    authors: Doggrell SA

    更新日期:2012-08-01 00:00:00

  • An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy.

    abstract::Methylphenidate (MPH) is one of the most commonly prescribed medications to treat attention deficit hyperactivity disorder (ADHD). Despite the elevated rates of ADHD in children with epilepsy, few studies have examined the use of MPH in this population. Case reports have warned about new-onset seizures in patients tre...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.1.77

    authors: Baptista-Neto L,Dodds A,Rao S,Whitney J,Torres A,Gonzalez-Heydrich J

    更新日期:2008-01-01 00:00:00

  • Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection.

    abstract::At present, the nucleoside reverse transcriptase (RT) inhibitors and protease inhibitors (PI) have dominated the therapeutic options for the treatment of human immunodeficiency virus (HIV) infection. From the initial monotherapeutic strategies, to the widely accepted multi-drug cocktails of today, the use of these two...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.8.1423

    authors: Buckheit RW

    更新日期:2001-08-01 00:00:00

  • Efalizumab for psoriasis?

    abstract::Psoriasis is a chronic skin disorder characterised by inflammation producing red, thickened areas with a flaky white build-up. Efalizumab is a humanised monoclonal IgG1 antibody that inhibits the binding of T lymphocytes to endothelial cells and their subsequent migration. In patients suffering from plaque psoriasis, ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.13.5.551

    authors: Doggrell SA

    更新日期:2004-05-01 00:00:00

  • Cardiac fibrosis: emerging agents in preclinical and clinical development.

    abstract:INTRODUCTION:Myocardial fibrosis is a remarkably dynamic process mediated by different molecular pathways that represent potential targets of novel therapeutic interventions. Transforming Growth Factor-beta (TGF-β), connective Tissue Growth Factor (cTGF) and Galectin-3 (Gal-3) represent the most promising targets on wh...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2021.1868432

    authors: Spoladore R,Falasconi G,Fiore G,Di Maio S,Preda A,Slavich M,Margonato A,Fragasso G

    更新日期:2021-01-04 00:00:00

  • Novel glucocorticoid receptor agonists in the treatment of asthma.

    abstract:INTRODUCTION:Inhaled corticosteroids are the only drugs that effectively suppress the airway inflammation, but they can induce considerable systemic and adverse effects when they are administered chronically at high doses. Consequently, the pharmaceutical industry is still searching for newer entities with an improved ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2015.1078310

    authors: Cazzola M,Coppola A,Rogliani P,Matera MG

    更新日期:2015-01-01 00:00:00

  • Combination therapy with the type II anti-CD20 antibody obinutuzumab.

    abstract:INTRODUCTION:Obinutuzumab is a novel humanized type II glycoengineered anti-CD20 antibody approved for first-line treatment of chronic lymphocytic leukemia (CLL) in combination with chlorambucil and for treatment of rituximab-refractory follicular lymphoma (FL). Areas covered: We describe current preclinical and clinic...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1373087

    authors: Klein C,Bacac M,Umana P,Fingerle-Rowson G

    更新日期:2017-10-01 00:00:00

  • ENMD-2076 for hematological malignancies.

    abstract:INTRODUCTION:Aurora kinases are key regulators of mitosis and inhibition of Aurora kinase activity is a rational therapeutic strategy in the treatment of solid tumors and hematological malignancies. AREAS COVERED:This paper will provide an updated summary of preclinical and clinical experience with ENMD-2076 in hemato...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.668882

    authors: How J,Yee K

    更新日期:2012-05-01 00:00:00